摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (4S)-5-hydroxy-4-[(1S)-1-(methoxymethoxy)hexyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4,5-dihydroimidazole-1-carboxylate | 1593758-74-7

中文名称
——
中文别名
——
英文名称
tert-butyl (4S)-5-hydroxy-4-[(1S)-1-(methoxymethoxy)hexyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4,5-dihydroimidazole-1-carboxylate
英文别名
——
tert-butyl (4S)-5-hydroxy-4-[(1S)-1-(methoxymethoxy)hexyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4,5-dihydroimidazole-1-carboxylate化学式
CAS
1593758-74-7
化学式
C21H39N3O7
mdl
——
分子量
445.557
InChiKey
AQWNHHWFDCZONM-KSCSMHSMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    31
  • 可旋转键数:
    13
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    119
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为反应物:
    描述:
    tert-butyl (4S)-5-hydroxy-4-[(1S)-1-(methoxymethoxy)hexyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4,5-dihydroimidazole-1-carboxylate 在 palladium on activated carbon 、 氢气 作用下, 以 二氯甲烷乙酸乙酯 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 36.0h, 生成 methyl (4R,5S)-4-[2,3-bis(t-butoxycarbonyl)guanidino]-5-(methoxymethoxy)decanoate
    参考文献:
    名称:
    A New Stereocontrolled Total Synthesis of the Mast Cell Inhibitory Alkaloid, (+)-Monanchorin, via the Wittig Reaction of a Stabilized Ylide with a Cyclic Guanidine Hemiaminal
    摘要:
    An asymmetric total synthesis of the mast cell inhibitor (+)-monanchorin is reported in which a Sharpless AD on 11 and a cyclic sulfate ring opening with an azide feature as key steps. After further manipulation, a novel guanidine-controlled ester reduction provided the guanidine-hemiaminal 25 which underwent Wittig olefination to give 27. Hydrogenation and a second guanidine-controlled reduction of the ester in 28, to obtain aldehyde 29, then set up a trifluoroacetic acid mediated cyclization to give (+)-monanchorin TFA salt.
    DOI:
    10.1021/ol500616v
  • 作为产物:
    描述:
    反式-2-辛烯甲酯氯化亚砜 、 sodium azide 、 甲基磺酰胺 、 20% palladium hydroxide-activated charcoal 、 AD-mix-α 、 氢气二异丁基氢化铝silver nitrate三乙胺N,N-二异丙基乙胺 作用下, 以 正己烷二氯甲烷乙酸乙酯N,N-二甲基甲酰胺丙酮甲苯叔丁醇 为溶剂, -78.0~50.0 ℃ 、101.33 kPa 条件下, 反应 200.08h, 生成 tert-butyl (4S)-5-hydroxy-4-[(1S)-1-(methoxymethoxy)hexyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4,5-dihydroimidazole-1-carboxylate
    参考文献:
    名称:
    A New Stereocontrolled Total Synthesis of the Mast Cell Inhibitory Alkaloid, (+)-Monanchorin, via the Wittig Reaction of a Stabilized Ylide with a Cyclic Guanidine Hemiaminal
    摘要:
    An asymmetric total synthesis of the mast cell inhibitor (+)-monanchorin is reported in which a Sharpless AD on 11 and a cyclic sulfate ring opening with an azide feature as key steps. After further manipulation, a novel guanidine-controlled ester reduction provided the guanidine-hemiaminal 25 which underwent Wittig olefination to give 27. Hydrogenation and a second guanidine-controlled reduction of the ester in 28, to obtain aldehyde 29, then set up a trifluoroacetic acid mediated cyclization to give (+)-monanchorin TFA salt.
    DOI:
    10.1021/ol500616v
点击查看最新优质反应信息

文献信息

  • A New Stereocontrolled Total Synthesis of the Mast Cell Inhibitory Alkaloid, (+)-Monanchorin, via the Wittig Reaction of a Stabilized Ylide with a Cyclic Guanidine Hemiaminal
    作者:Karl J. Hale、Liping Wang
    DOI:10.1021/ol500616v
    日期:2014.4.18
    An asymmetric total synthesis of the mast cell inhibitor (+)-monanchorin is reported in which a Sharpless AD on 11 and a cyclic sulfate ring opening with an azide feature as key steps. After further manipulation, a novel guanidine-controlled ester reduction provided the guanidine-hemiaminal 25 which underwent Wittig olefination to give 27. Hydrogenation and a second guanidine-controlled reduction of the ester in 28, to obtain aldehyde 29, then set up a trifluoroacetic acid mediated cyclization to give (+)-monanchorin TFA salt.
查看更多

同类化合物

(4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] 香豆素-6-羧酸 锌离子载体IV 钐(III) 离子载体 II 苯,(2,2-二氟乙烯基)- 聚二硫二噻唑烷 缩胆囊肽9 甲酰乙内脲 甲巯咪唑 甲基羟甲基油基噁唑啉 甲基5-羟基-3,5-二甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-氰基-4,5-二氢-1,2-恶唑-3-羧酸酯 甲基5-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-5-氧代-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4,5-二氮杂螺[2.4]庚-5-烯-6-羧酸酯 甲基4,5-二氢-5-乙基-1H-吡唑-1-羧酸酯 甲基(E)-3-[6-[1-羟基-1-(4-甲基苯基)-3-(1-吡咯烷基)丙基]-2-吡啶基]丙烯酰酸酯 甲基(5-氧代-4,5-二氢-1,2-恶唑-3-基)乙酸酯 环戊二烯并[d]咪唑-2,5(1H,3H)-二硫酮 溶剂黄93 溴化1-十六烷基-3-甲基咪唑 溴化1-十二烷基-2,3-二甲基咪唑 泰比培南酯中间体 泰比培南酯中间体 氨基甲硫酸,[2-[[(2-羰基-1-咪唑烷基)硫代甲基]氨基]乙基]-,O-甲基酯 异噻唑,4,5-二氯-2,5-二氢-2-辛基- 希诺米啉 四氟硼酸二氢1,3-二(叔-丁基)-4,5--1H-咪唑正离子 四唑硝基紫 噻唑丁炎酮 噻唑,4,5-二氢-4-(1-甲基乙基)-,(S)- 噁唑,4,5-二氢-4,4-二甲基-2-(5-甲基-2-呋喃基)- 噁唑,2-庚基-4,5-二氢- 咪唑烷基脲 吡嗪,2,3-二氢-5,6-二甲基-2-丙基- 叔-丁基3-羟基-1,4,6,7-四氢吡唑并[4,3-c]吡啶-5-羧酸酯 双吡唑啉酮 双[(S)-4-异丙基-4,5-二氢噁唑-2-基]甲烷 双((R)-4-(叔丁基)-4,5-二氢恶唑-2-基)甲烷 利美尼啶D4 利美尼啶 假硫代乙内酰脲 依达拉奉杂质DO 依达拉奉杂质 依达拉奉三聚体 依达拉奉 仲班酸